Your shopping cart is currently empty

Deoxyelephantopin has anti-inflammatory, hepatoprotective, and wound healing activities; it also has antitumor activity.Deoxyelephantopin inhibits NF-κB, MAPK, PI3K/Akt, and β-catenin signaling

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $97 | In Stock | In Stock | |
| 5 mg | $247 | In Stock | In Stock | |
| 10 mg | $368 | In Stock | In Stock | |
| 25 mg | $596 | In Stock | In Stock | |
| 50 mg | $863 | - | In Stock | |
| 1 mL x 10 mM (in DMSO) | $253 | In Stock | In Stock |
| Description | Deoxyelephantopin has anti-inflammatory, hepatoprotective, and wound healing activities; it also has antitumor activity.Deoxyelephantopin inhibits NF-κB, MAPK, PI3K/Akt, and β-catenin signaling |
| In vitro | Deoxyelephantopin was evaluated for its effects on the expression of mRNAs encoding CYP1A2, CYP2D6 and CYP3A4, and protein expression and resultant enzymatic activity. The mRNA and protein expression of cytochrome isoforms were carried out using an optimized multiplex qRT-PCR assay and Western blot analysis, respectively. Human CYP3A4 protein expression was determined using an optimized hCYP3A4-HepG2 cell-based assay and the enzymatic activity was evaluated using P450-Glo CYP3A4 assay. The molecular interaction and possible inhibition of Deoxyelephantopin of the CYP3A4 enzyme was determined in silico and further validated using substrate-specific CYP3A4 inhibition assays. Deoxyelephantopin produced no significant effect on the CYP1A2 and CYP2D6 mRNA and protein expression. However, it has a weak induction effect on CYP3A4 at the transcriptional level[1] |
| Molecular Weight | 344.36 |
| Formula | C19H20O6 |
| Cas No. | 29307-03-7 |
| Smiles | [H][C@@]12C\C(C)=C/[C@@]3([H])OC(=O)C(=C)[C@]3([H])[C@H](CC(=C1)C(=O)O2)OC(=O)C(C)=C |
| Relative Density. | 1.26g/cm3 |
| Storage | store at low temperature,keep away from moisture,keep away from direct sunlight | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 100 mg/mL (290.39 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+90% Corn Oil: 3.3 mg/mL (9.58 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.